mygn-20210630
false000089992312/312021Q200008999232021-01-012021-06-30xbrli:shares00008999232021-07-28iso4217:USD00008999232021-06-3000008999232020-12-310000899923mygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-3000008999232021-04-012021-06-3000008999232020-04-012020-06-3000008999232020-01-012020-06-30iso4217:USDxbrli:shares0000899923us-gaap:CommonStockMember2019-12-310000899923us-gaap:AdditionalPaidInCapitalMember2019-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000899923us-gaap:RetainedEarningsMember2019-12-310000899923us-gaap:NoncontrollingInterestMember2019-12-3100008999232019-12-310000899923us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100008999232020-01-012020-03-310000899923us-gaap:NoncontrollingInterestMember2020-01-012020-03-310000899923us-gaap:RetainedEarningsMember2020-01-012020-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000899923us-gaap:CommonStockMember2020-03-310000899923us-gaap:AdditionalPaidInCapitalMember2020-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310000899923us-gaap:RetainedEarningsMember2020-03-310000899923us-gaap:NoncontrollingInterestMember2020-03-3100008999232020-03-310000899923us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000899923us-gaap:RetainedEarningsMember2020-04-012020-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000899923us-gaap:CommonStockMember2020-06-300000899923us-gaap:AdditionalPaidInCapitalMember2020-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000899923us-gaap:RetainedEarningsMember2020-06-300000899923us-gaap:NoncontrollingInterestMember2020-06-3000008999232020-06-300000899923us-gaap:CommonStockMember2020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2020-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000899923us-gaap:RetainedEarningsMember2020-12-310000899923us-gaap:NoncontrollingInterestMember2020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100008999232021-01-012021-03-310000899923us-gaap:RetainedEarningsMember2021-01-012021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000899923us-gaap:CommonStockMember2021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000899923us-gaap:RetainedEarningsMember2021-03-310000899923us-gaap:NoncontrollingInterestMember2021-03-3100008999232021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000899923us-gaap:NoncontrollingInterestMember2021-04-012021-06-300000899923us-gaap:RetainedEarningsMember2021-04-012021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000899923us-gaap:CommonStockMember2021-06-300000899923us-gaap:AdditionalPaidInCapitalMember2021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000899923us-gaap:RetainedEarningsMember2021-06-300000899923us-gaap:NoncontrollingInterestMember2021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923country:US2021-04-012021-06-300000899923us-gaap:NonUsMember2021-04-012021-06-300000899923country:US2020-04-012020-06-300000899923us-gaap:NonUsMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923country:US2021-01-012021-06-300000899923us-gaap:NonUsMember2021-01-012021-06-300000899923country:US2020-01-012020-06-300000899923us-gaap:NonUsMember2020-01-012020-06-3000008999232019-07-012020-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2021-01-012021-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2021-04-012021-06-30xbrli:pure0000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300000899923mygn:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300000899923us-gaap:CashMember2021-06-300000899923us-gaap:CashEquivalentsMember2021-06-300000899923us-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:USTreasuryAndGovernmentMember2021-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923us-gaap:CashMember2020-12-310000899923us-gaap:CashEquivalentsMember2020-12-310000899923us-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:USTreasuryAndGovernmentMember2020-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-31mygn:security0000899923us-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-06-300000899923us-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:MoneyMarketFundsMember2021-06-300000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2021-06-300000899923us-gaap:FairValueInputsLevel3Membermygn:ContingentConsiderationMember2021-06-300000899923mygn:ContingentConsiderationMember2021-06-300000899923us-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Member2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000899923us-gaap:MoneyMarketFundsMember2020-12-310000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2020-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2020-12-310000899923us-gaap:FairValueInputsLevel3Membermygn:ContingentConsiderationMember2020-12-310000899923mygn:ContingentConsiderationMember2020-12-310000899923us-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Member2020-12-310000899923us-gaap:FairValueInputsLevel3Member2020-12-310000899923mygn:MyriadAutoimmuneAssetsAndMyriadRBMIncMember2021-04-012021-06-300000899923us-gaap:LeaseholdImprovementsMember2021-06-300000899923us-gaap:LeaseholdImprovementsMember2020-12-310000899923us-gaap:EquipmentMember2021-06-300000899923us-gaap:EquipmentMember2020-12-310000899923mygn:DiagnosticsMember2020-12-310000899923us-gaap:AllOtherSegmentsMember2020-12-310000899923mygn:DiagnosticsMember2021-01-012021-06-300000899923us-gaap:AllOtherSegmentsMember2021-01-012021-06-300000899923mygn:DiagnosticsMember2021-06-300000899923us-gaap:AllOtherSegmentsMember2021-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2021-06-300000899923us-gaap:CustomerRelationshipsMember2021-06-300000899923us-gaap:TrademarksMember2021-06-300000899923mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember2021-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2020-12-310000899923us-gaap:CustomerRelationshipsMember2020-12-310000899923us-gaap:TrademarksMember2020-12-310000899923mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember2020-12-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2018-07-312018-07-310000899923us-gaap:RevolvingCreditFacilityMember2016-12-230000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2018-07-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2020-12-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2021-02-210000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2021-09-300000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2021-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-012022-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2020-04-012022-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-07-012022-07-010000899923srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-07-012022-07-010000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMembermygn:AmendmentToCreditAgreementMember2022-07-012022-07-010000899923srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2022-07-012022-07-010000899923us-gaap:RevolvingCreditFacilityMember2021-01-012021-06-300000899923us-gaap:RevolvingCreditFacilityMember2020-07-012020-12-310000899923mygn:EighthShareRepurchaseProgramMember2016-06-300000899923mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember2021-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300000899923mygn:NonEmployeeDirectorMembermygn:OptionsAndRestrictedStockUnitsMember2021-01-012021-06-300000899923us-gaap:EmployeeStockOptionMember2021-01-012021-06-300000899923mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMemberus-gaap:EmployeeStockOptionMember2021-01-012021-06-300000899923us-gaap:EmployeeStockOptionMembermygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMember2021-01-012021-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2020-12-310000899923us-gaap:RestrictedStockUnitsRSUMember2021-06-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2021-01-012021-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMemberus-gaap:EarliestTaxYearMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMemberus-gaap:LatestTaxYearMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:EarliestTaxYearMemberus-gaap:SwissFederalTaxAdministrationFTAMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:LatestTaxYearMemberus-gaap:SwissFederalTaxAdministrationFTAMember2021-01-012021-06-30mygn:segment0000899923mygn:DiagnosticsMember2021-04-012021-06-300000899923us-gaap:AllOtherSegmentsMember2021-04-012021-06-300000899923mygn:DiagnosticsMember2020-04-012020-06-300000899923us-gaap:AllOtherSegmentsMember2020-04-012020-06-300000899923mygn:DiagnosticsMember2020-01-012020-06-300000899923us-gaap:AllOtherSegmentsMember2020-01-012020-06-300000899923mygn:MyriadMyPathLLCLaboratoryMember2021-05-282021-05-280000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermygn:MyriadAutoimmuneAssetsMember2021-05-010000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermygn:MyriadRBMIncMember2021-05-210000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-04-012021-06-300000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadRBMIncMemberus-gaap:SubsequentEventMember2021-07-010000899923us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMember2021-07-010000899923us-gaap:SubsequentEventMember2021-07-312021-07-310000899923us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMember2021-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________
FORM 10-Q
_________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to           
Commission file number:  0-26642
_________________________________________
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
_________________________________________
Delaware
(State or other jurisdiction
of incorporation or organization)
320 Wakara Way, Salt Lake City, UT
(Address of principal executive offices)
87-0494517
(I.R.S. Employer Identification No.)

84108
(Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
_________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par valueMYGNNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x
As of July 28, 2021, the registrant had 78,055,365 shares of $0.01 par value common stock outstanding.




MYRIAD GENETICS, INC.
INDEX TO FORM 10-Q
Page

3

Table of Contents


MYRIAD GENETICS, INC.
Condensed Consolidated Balance Sheets
(in millions)
June 30,
2021
December 31,
2020
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$118.4 $117.0 
Marketable investment securities46.0 33.7 
Trade accounts receivable94.8 89.5 
Inventory17.7 27.1 
Assets held for sale225.7  
Prepaid taxes18.6 108.4 
Prepaid expenses and other current assets17.7 13.7 
Total current assets538.9 389.4 
Operating lease right-of-use assets86.6 59.7 
Long-term marketable investment securities19.9 21.0 
Property, plant, and equipment, net43.2 40.7 
Intangibles, net426.8 576.5 
Goodwill240.1 329.2 
Other assets4.8 2.3 
Total assets$1,360.3 $1,418.8 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$28.5 $20.5 
Accrued liabilities90.9 79.1 
Current maturities of operating lease liabilities12.7 13.6 
Deferred revenues22.6 32.7 
Liabilities held for sale12.2  
Current portion of long-term debt104.1  
Total current liabilities271.0 145.9 
Unrecognized tax benefits31.0 30.5 
Long-term deferred taxes58.2 71.3 
Noncurrent operating lease liabilities83.9 50.6 
Long-term debt 224.8 
Other long-term liabilities13.8 14.7 
Total liabilities457.9 537.8 
Commitments and contingencies
Stockholders’ equity:
Common stock, 77.7 million and 75.4 million shares outstanding at June 30,
2021 and December 31, 2020, respectively
0.8 0.8 
Additional paid-in capital1,176.9 1,109.5 
Accumulated other comprehensive loss(4.0)(2.3)
Accumulated deficit(271.2)(227.0)
Total Myriad Genetics, Inc. stockholders’ equity902.5 881.0 
Non-controlling interest(0.1) 
Total stockholders' equity902.4 881.0 
Total liabilities and stockholders’ equity$1,360.3 $1,418.8 
See accompanying notes to Condensed Consolidated Financial Statements.
4

Table of Contents
MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Operations (unaudited)
(in millions, except per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2021202020212020
Revenues:
Molecular diagnostic testing$178.7 $83.3 $338.3 $233.8 
Pharmaceutical and clinical services10.7 9.9 24.2 23.4 
Total revenue189.4 93.2 362.5 257.2 
Costs and expenses:
Cost of molecular diagnostic testing48.0 32.2 92.1 75.3 
Cost of pharmaceutical and clinical services5.7 4.5 11.9 11.5 
Research and development expense19.5 17.4 42.6 37.1 
Selling, general, and administrative expense134.8 107.4 280.3 240.3 
Change in the fair value of contingent consideration0.4  1.3 (3.4)
Goodwill and long-lived asset impairment charges1.8  1.8 98.4 
Total costs and expenses210.2 161.5 430.0 459.2 
Operating loss(20.8)(68.3)(67.5)(202.0)
Other income (expense):
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Total other income, net17.0 9.8 14.1 12.4 
Loss before income tax(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest (0.1) (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
Net loss per share:
Basic and diluted$(0.06)$(0.74)$(0.58)$(2.29)
Weighted average shares outstanding:
Basic and diluted77.2 74.6 76.6 74.6 
See accompanying notes to Condensed Consolidated Financial Statements.
5

Table of Contents
MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
(in millions)
Three months ended
June 30,
Six months ended
June 30,
2021202020212020
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
Unrealized loss on available-for-sale debt securities, net of tax(0.1)0.8 (0.3)0.7 
Change in foreign currency translation adjustment, net of tax(0.3)1.8 (1.4)(0.7)
Comprehensive loss(5.1)(52.8)(45.9)(170.6)
Comprehensive loss attributable to non-controlling interest    
Comprehensive loss attributable to Myriad Genetics, Inc. stockholders$(5.1)$(52.8)$(45.9)$(170.6)
See accompanying notes to Condensed Consolidated Financial Statements.
6

Table of Contents
MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in millions)
Common
stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Non-controlling interestTotal
stockholders’
equity
BALANCES AT DECEMBER 31, 2019$0.7 $1,085.1 $(5.3)$(3.3)$0.1 $1,077.3 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 0.2 — — — 0.2 
Stock-based payment expense— 7.5 — — — 7.5 
Non-controlling interest— — — — (0.1)(0.1)
Net loss— — — (115.2)— (115.2)
Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary— — 0.1 — — 0.1 
Other comprehensive loss, net of tax— — (2.6)— — (2.6)
BALANCES AT MARCH 31, 2020$0.7 $1,092.8 $(7.8)$(118.5)$ $967.2 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 1.9 — — — 1.9 
Stock-based payment expense— 1.9 — — — 1.9 
Net loss— — — (55.4)— (55.4)
Other comprehensive income, net of tax— — 2.6 — — 2.6 
BALANCES AT JUNE 30, 2020$0.7 $1,096.6 $(5.2)$(173.9)$ $918.2 
BALANCES AT DECEMBER 31, 2020$0.8 $1,109.5 $(2.3)$(227.0)$ $881.0 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 26.0 — — — 26.0 
Stock-based payment expense— 9.0 — — — 9.0 
Net loss— — — (39.5)— (39.5)
Other comprehensive loss, net of tax— — (1.3)— — (1.3)
BALANCES AT MARCH 31, 2021$0.8 $1,144.5 $(3.6)$(266.5)$ $875.2 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 23.5 — — — 23.5 
Stock-based payment expense— 8.9 — — — 8.9 
Non-controlling interest— — — — (0.1)(0.1)
Net loss— — — (4.7)— (4.7)
Other comprehensive loss, net of tax— — (0.4)— — (0.4)
BALANCES AT JUNE 30, 2021$0.8 $1,176.9 $(4.0)$(271.2)$(0.1)$902.4 
See accompanying notes to Condensed Consolidated Financial Statements.
7

Table of Contents
MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)
Six months ended
June 30,
20212020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Myriad Genetics, Inc. stockholders$(44.2)$(170.6)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization35.3 35.6 
Non-cash interest expense0.8 0.3 
Non-cash lease expense6.8 6.3 
Stock-based compensation expense17.9 9.4 
Deferred income taxes(11.5)(49.0)
Unrecognized tax benefits0.4 1.0 
Change in fair value of contingent consideration1.3 (3.4)
Loss on inventory6.6  
Impairment of goodwill and long-lived assets1.8 98.4 
Gain on deconsolidation of subsidiary (1.0)
Gain on sale of assets(32.4) 
Changes in assets and liabilities:
Prepaid expenses(4.7)2.4 
Trade accounts receivable(12.3)50.3 
Other receivables0.3 0.9 
Inventory(0.8)(0.9)
Prepaid taxes89.8 24.7 
Other assets(2.7) 
Accounts payable8.1 0.6 
Accrued liabilities16.1 12.7 
Deferred revenue(9.2)29.1 
Net cash provided by operating activities67.4 46.8 
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(11.6)(5.3)
Proceeds from sale of subsidiary 21.3 
Proceeds from sale of assets32.5  
Purchases of marketable investment securities(36.6)(15.8)
Proceeds from maturities and sales of marketable investment securities25.0 33.4 
Net cash provided by investing activities9.3 33.6 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans50.1 2.2 
Payment of tax withheld for common stock issued under stock-based compensation plans(0.6)(0.1)
Payment of contingent consideration recognized at acquisition(3.3) 
Fees associated with refinancing of revolving credit facility(1.2)(1.0)
Repayment of revolving credit facility(120.0) 
Net cash provided by (used in) financing activities(75.0)1.1 
Effect of foreign exchange rates on cash and cash equivalents(0.3)(0.5)
Change in cash and cash equivalents classified as held for sale 1.5 
Net increase in cash and cash equivalents1.4 82.5 
Cash and cash equivalents at beginning of the period117.0 81.2 
Cash and cash equivalents at end of the period$118.4 $163.7 
See accompanying notes to Condensed Consolidated Financial Statements.
8

Table of Contents
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1.BASIS OF PRESENTATION
Myriad Genetics, Inc. and subsidiaries (collectively, the “Company” or “Myriad”) discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah.
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30. Additionally, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible.
Due to the COVID-19 global pandemic (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impacts of COVID-19, including variants of COVID-19, on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. The Company is not able to estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.
Held for Sale Policy
Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.

Recent Accounting Pronouncements
Recently Adopted Standards
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted with no material impact to the Company's Condensed Consolidated Financial Statements.
9

Table of Contents
2.REVENUE
Myriad generates revenue by performing molecular diagnostic testing and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Autoimmune (Vectra), and Other. The Company previously provided clinical services until selling Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 as described in Note 16, Myriad myPath revenue was included in Other within molecular diagnostic revenues. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.
The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
Three months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$73.8 $12.2 $86.0 $34.9 $5.0 $39.9 
Tumor Profiling18.1 11.1 29.2 8.6 1.9 10.5 
Prenatal29.2 0.2 29.4 16.5 0.1 16.6 
Pharmacogenomics22.6  22.6 8.5  8.5 
Autoimmune10.2  10.2 7.3  7.3 
Other0.2 1.1 1.3 0.5  0.5 
Total molecular diagnostic revenue154.1 24.6 178.7 76.3 7.0 83.3 
Pharmaceutical and clinical service revenue10.7  10.7 9.9  9.9 
Total revenue$164.8 $24.6 $189.4 $86.2 $7.0 $93.2 
Six months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$138.9 $23.2 $162.1 $116.2 $8.9 $125.1 
Tumor Profiling42.3 17.9 60.2 19.3 4.9 24.2 
Prenatal52.8 0.3 53.1 36.7 0.2 36.9 
Pharmacogenomics40.2  40.2 28.9  28.9 
Autoimmune20.9  20.9 17.7  17.7 
Other0.2 1.6 1.8 1.0  1.0 
Total molecular diagnostic revenue295.3 43.0 338.3 219.8 14.0 233.8 
Pharmaceutical and clinical service revenue24.2  24.2 19.5 3.9 23.4 
Total revenue$319.5 $43.0 $362.5 $239.3 $17.9 $257.2 
The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
10

Table of Contents
Six months ended
June 30,
(in millions)20212020
Deferred revenue - beginning balance$32.7 $3.6 
Revenue recognized(15.5)(6.1)
Prepayments6.3 35.3 
Held for sale reclassification(0.9) 
Deferred revenue - ending balance$22.6 $32.8 
In accordance with ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2021, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $6.7 million. 

11

Table of Contents
In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices.

The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and six months ended June 30, 2021, the Company recognized $13.3 million and $13.2 million in revenue, respectively, which resulted in a $0.13 impact to earnings per share to each period for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period.
The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 16% and 18% of total revenue for the three and six months ended June 30, 2021, respectively, and 12% and 15% of total revenue for the three and six months ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. Medicare accounted for 11% of accounts receivable at June 30, 2021. No payor accounted for more than 10% of accounts receivable at December 31, 2020. The Company does not require collateral from its customers.

12

Table of Contents
3.MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
June 30, 2021
Cash and cash equivalents:
Cash$60.4 $— $— $60.4 
Cash equivalents58.0 — — 58.0 
Total cash and cash equivalents118.4 — — 118.4 
Available-for-sale:
Corporate bonds and notes46.1 0.3  46.4 
Municipal bonds13.2 0.1  13.3 
Federal agency issues2.5   2.5 
US government securities3.7   3.7 
Total$183.9 $0.4 $ $184.3 
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
December 31, 2020:
Cash and cash equivalents:
Cash$47.9 $— $— $47.9 
Cash equivalents69.1 — — 69.1 
Total cash and cash equivalents117.0 — — 117.0 
Available-for-sale:
Corporate bonds and notes28.8 0.5  29.3 
Municipal bonds9.4 0.2  9.6 
Federal agency issues4.0   4.0 
US government securities11.7 0.1  11.8 
Total$170.9 $0.8 $ $171.7 

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:
(in millions)Amortized
cost
Estimated
fair value
Cash$60.4 $60.4 
Cash equivalents58.0 58.0 
Available-for-sale:
Due within one year45.8 46.0 
Due after one year through five years19.7 19.9 
Due after five years  
Total$183.9 $184.3 

There were no debt securities classified as available-for-sale in a gross unrealized loss position as of June 30, 2021 or December 31, 2020.

Additional information relating to fair value of marketable investment securities can be found in Note 4.


13

Table of Contents
4.FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 14.0 years, utilizing various potential pay-out scenarios.  Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.  Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.
The fair value of the Company’s long-term debt, which it considers a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements.  The fair value of the Company's long-term debt is estimated to be $106.0 million at June 30, 2021. As of June 30, 2021, the Company intended to pay off the remaining balance of debt during the quarter ended September 30, 2021. As such, long-term debt was reclassified to Current portion of long-term debt in the Company's Condensed Consolidated Balance Sheets as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility (as defined in Note 8) on July 30, 2021, which is described in Note 17.
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2021
Money market funds (a)$58.0 $ $ $58.0 
Corporate bonds and notes 46.4  46.4 
Municipal bonds 13.3  13.3 
Federal agency issues 2.5  2.5 
US government securities 3.7  3.7 
Contingent consideration  (8.5)(8.5)
Total$58.0 $65.9 $(8.5)$115.4 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

14

Table of Contents
(in millions)Level 1Level 2Level 3Total
December 31, 2020
Money market funds (a)$69.1 $ $ $69.1 
Corporate bonds and notes 29.3  29.3 
Municipal bonds 9.6  9.6 
Federal agency issues 4.0  4.0 
US government securities 11.8  11.8 
Contingent consideration  (10.9)(10.9)
Total$69.1 $54.7 $(10.9)$112.9 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

Nonrecurring Fair Value Measurements
In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements.

As a result of the approval of the Company's Board of Directors to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit during the quarter ended June 30, 2021, the Company performed an interim impairment analysis for the assets held for sale. The Company did not recognize any impairment charges on the asset groups classified as held for sale. The fair value used in the analysis, which the Company considers a Level 2 measurement, was based on the sale prices of Myriad RBM, Inc. and the Myriad Autoimmune assets.

The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance December 31, 2020$10.9 
Payment of contingent consideration(3.3)
Change in fair value recognized in the income statement1.3 
Translation adjustments recognized in other comprehensive loss(0.4)
Ending balance June 30, 2021$8.5 

5.PROPERTY, PLANT AND EQUIPMENT, NET
(in millions)June 30,
2021
December 31,
2020
Leasehold improvements$36.5 $35.7 
Equipment109.6 117.9 
Property, plant and equipment, gross146.1 153.6 
Less accumulated depreciation(102.9)(112.9)
Property, plant and equipment, net$43.2 $40.7 

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Depreciation expense$3.4 $2.5 $6.3 $5.1 


15